T1G3 transitional cell carcinoma of the bladder: Recurrence, progression and survival

BJU International

Volumn 93, Issue 1, 2004, Pages 60-63

  Peyromaure, M ^a   Zerbib, M ^a  

^a Cochin Hospital ^*  (France)

Author keywords

BCG; Bladder cancer; Chemotherapy; Immunotherapy; T1G3

Indexed keywords

BCG VACCINE; MITOMYCIN C;

ADULT; AGED; ARTICLE; BIOPSY; BLADDER CARCINOMA; CANCER SURVIVAL; CONTROLLED STUDY; CYSTECTOMY; DISEASE COURSE; DRUG INSTILLATION; FEMALE; FOLLOW UP; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTIMODALITY CANCER THERAPY; PRIORITY JOURNAL; RECURRENT DISEASE; SURVIVAL RATE; SURVIVAL TIME; TRANSITIONAL CELL CARCINOMA; TREATMENT OUTCOME;

ADJUVANTS, IMMUNOLOGIC; ADMINISTRATION, INTRAVESICAL; ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS; BCG VACCINE; CARCINOMA, TRANSITIONAL CELL; COMBINED MODALITY THERAPY; CYSTECTOMY; DISEASE PROGRESSION; FEMALE; FOLLOW-UP STUDIES; HUMANS; IMMUNOTHERAPY; MALE; MIDDLE AGED; MITOMYCIN; NEOPLASM RECURRENCE, LOCAL; RETROSPECTIVE STUDIES; SURVIVAL ANALYSIS; TREATMENT OUTCOME; URINARY BLADDER NEOPLASMS;

EID: 1642538377     PISSN: 14644096     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1464-410X.2004.04556.x     Document Type: Article

References (20)

1. Anderstrom C, Johansson S, Nilsson S. The significance of lamina propria invasion on the prognosis of patients with bladder tumors. J Urol 1980; 124: 23-6
2. Morales A, Eidinger D, Bruce AW. Intracavitary bacillus Calmette-Guérin in the treatment of superficial bladder tumors. J Urol 1976; 116: 180-3
3. Patard JJ, Moudouni S, Saint F et al. Tumor progression and survival in patients with T1G3 bladder tumors: multicentric retrospective study comparing 94 patients treated during 17 years. Urology 2001; 58: 551-6
4. Krege S, Giani G, Meyer R, Otto T, Rubben H. A randomized multicenter trial of adjuvant therapy in superficial bladder cancer: transurethral resection only versus transurethral resection plus mitomycin C versus transurethral resection plus bacillus Calmette-Guerin. Participating clinics. J Urol 1996; 156: 962-6
5. Pansadoro V, Emiliozzi P, Defidio L et al. Bacillus Calmette-Guerin in the treatment of stage T1 grade 3 transitional cell carcinoma of the bladder: long-term results. J Urol 1995; 154: 2054-8
6. Baniel J, Grauss D, Engelstein D, Sella A. Intravesical bacillus Calmette-Guerin treatment for stage T1 grade 3 transitional cell carcinoma of the bladder. Urology 1998; 52: 785-9
7. Lebret T, Gaudez F, Herve JM, Barre P, Lugagne PM, Botto H. Low-dose BCG instillations in the treatment of stage T1 grade 3 bladder tumours: recurrence, progression and success. Eur Urol 1998; 34: 67-72
8. Hurle R, Losa A, Manzetti A, Lembo A. Intravesical bacille Calmette-Guerin in stage T1G3 bladder cancer therapy: a 7-year follow-up. Urology 1999; 54: 258-63
9. Kulkarni JN, Gupta R. Recurrence and progression in stage bladder tumour with intravesical bacille Calmette-Guérin (Danish 1331 strain). BJU Int 2002; 90: 554-7
10. Solsona E, Iborra I, Ricos JV, Monros JL, Casanova J, Dumont R. Effectiveness of a single immediate mitomycin C instillation in patients with low risk superficial bladder cancer: short and long-term followup. J Urol 1999; 161: 1120-3
11. Herr HW. Tumour progression and survival in patients with T1G3 bladder tumours: 15-year outcome. Br J Urol 1997; 80: 762-5
12. Bono AV, Lovisolo JA, Saredi G. Transurethral resection and sequential chemo-immunoprophylaxis in primary T1G3 bladder cancer. Eur Urol 2000; 37: 478-83
13. Kolodziej A, Dembowski J, Zdrojowy R, Wozniak P, Lorenz J. Treatment of high-risk superficial bladder cancer with maintenance bacille Calmette-Guérin therapy: preliminary results. BJU Int 2002; 89: 620-2
14. Iori F, Di Seri M, De Nunzio C et al. Long-term maintenance bacille Calmette-Guerin therapy in high-grade superficial bladder cancer. Urology 2002; 59: 414-8
15. Palou J, Laguna P, Millan-Rodriguez F, Hall RR, Salvador-Bayarri J, Vicente-Rodriguez J. Control group and maintenance treatment with bacillus Calmette-Guerin for carcinoma in situ and/or high grade bladder tumors. J Urol 2001; 165: 1488-91
16. Lamm DL, Blumenstein BA, Crissman JD et al. Maintenance bacillus Calmette-Guerin immunotherapy for recurrent TA, T1 and carcinoma in situ transitional cell carcinoma of the bladder: a randomized Southwest Oncology Group Study. J Urol 2000; 163: 1124-9
17. Chang SS, Cookson MS, Baumgartner RG et al. Analysis of early complications after radical cystectomy: results of a collaborative care pathway. J Urol 2002; 167: 2012-6
18. Martinez-Pineiro JA, Flores N, Isorna S et al. Long-term follow-up of a randomized prospective trial comparing a standard 81 mg dose of intravesical bacille Calmette-Guerin with a reduced dose of 27 mg in superficial bladder cancer. BJU Int 2002; 89: 671-80
19. Borkowski A. Superficial bladder cancer T1G3. the choice of treatment. BJU Int 2002; 89: 623-7
20. Herr HW, Sogani PC. Does early cystectomy improve the survival of patients with high risk superficial bladder tumors? J Urol 2001; 166: 1296-9